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AbstrAct
background: The aim of the study was to evaluate the feasibility and safety of stereotactic body radiotherapy (sBrT) for the 
treatment of hepatocellular carcinoma in Brazil. sBrT is an evolving treatment in hcc patients not candidates to other local 
therapies. Its adoption in clinical practice has been heterogeneous, with lack of data on its generalizability in the Brazilian 
population. 
Materials and methods: We conducted a prospective pilot study involving hcc patients after failure or ineligibility for tran-
sarterial chemoembolization. patients received sBrT 30 to 50 Gy in 5 fractions using an isotoxic prescription approach. This 
study is registered at clinicaltrials.gov NcT02221778.
results: From Nov 2014 through aug 2019, 26 patients received sBrT with 40 Gy median dose. Underlying liver disease was 
hepatitis c, hepatitis B and alcohol-related in, respectively, 50%, 23% and 19% of patients. Median lesion size was 3.8 cm 
(range, 1.5–10 cm), and 46% had multiple lesions. Thirty-two percent had tumor vascular thrombosis; median pretreatment 
alpha-fetoprotein (aFp) was 171.7 ng/mL (range, 4.2–5,494 ng/mL). 1y-local progression-free survival (pFs) was 86% (95% cI: 
61% to 95%), with higher local control in doses ≥ 45Gy (p = 0.037; hr = 0.12). 1y-liver pFs, distant pFs and Os were, respec-
tively, 52%, 77% and 79%. Objective response was seen in 89% of patients, with 3 months post-sBrT median aFp of 12 ng/mL 
(2.4–637 ng/mL). There were no grade 3 or 4 clinical toxicities. Grade 3 or 4 laboratory toxicities occurred in 27% of patients. 
conclusion: sBrT is feasible and safe in patients unresponsive or ineligible for Tace in Brazil. Our study suggests doses 
≥ 45 Gy yields better local control. 
Key words: radiosurgery; stereotactic body radiotherapy; therapeutic chemoembolization; hepatocellular carcinoma; 
clinical trial
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Introduction
Hepatocellular carcinoma (HCC) is the 6th most 
commonly diagnosed cancer and the 4th leading 
cause of cancer death worldwide [1]. Incidence is 
close to mortality, highlighting tumor aggressive-
ness. The majority of cases are diagnosed in devel-
oping countries [1, 2]. 
In South America, the majority of patients is 
diagnosed at late stages, as reflected in Transarte-
rial Chemoembolization (TACE) being the most 
common treatment for HCC [3]. TACE improves 
survival mainly in patients without major vascular 
thrombosis [4, 5]. However, treatment efficacy is re-
duced after multiple sessions. TACE should not be 
repeated when substantial necrosis is not achieved 
after two rounds of treatment or when follow-up 
treatment fails to induce noticeable necrosis at sites 
that have progressed after an initial tumor response 
[6]. There is paucity of effective local therapies after 
failure or ineligibility for TACE [7, 8]. 
Stereotactic Body Radiotherapy (SBRT) is an 
emerging treatment option that uses highly focused 
radiation in few sessions to treat HCC. Phase I and 
II studies have shown encouraging results [9–16], 
but incorporation of SBRT by guidelines has been 
heterogeneous [6, 17–19]. Additionally, developing 
countries are underrepresented in the published 
literature of liver SBRT, with most studies coming 
from Asia, North America and Europe. In 2014, 
we initiated a prospective pilot study to evaluate 
the feasibility and safety of SBRT in patients un-
responsive or ineligible for TACE in the Brazilian 
population. 
Materials and methods
This was a single-arm prospective pilot study. 
Patients were recruited at Instituto do Cancer do 
Estado de Sao Paulo, an academic tertiary cancer 
center in Brazil. HCC diagnosis was according to 
the American Association for the Study of Liver 
Diseases (AASLD) 2010 guidelines [20]. Before en-
rolling, patients 1) had received at least two previous 
sessions of TACE and had remained with a viable 
tumor or 2) were ineligible for TACE (e.g., tumor 
vascular thrombosis (TVT), severe post-emboliza-
tion syndrome, medical comorbidities). 
Eligible patients had 1 to 5 HCC lesions with 
maximum diameter of 10 cm and no extra-hepatic 
disease. Uninvolved liver had to be ≥ 700 cc [21], 
accounting for at least 40% of total liver volume. 
All patients had Child-Pugh score A, Eastern Co-
operative Oncology Group (ECOG) performance 0 
to 1, hemoglobin ≥ 8 mg/dL, platelets ≥ 45 × 109/L, 
neutrophil count > 1.2 × 109/L, total bilirubin ≤ 2 
mg/dL, International Normalized Ratio (INR) < 1.7, 
alanine aminotransferase (ALT) and aspartate ami-
notransferase (AST) < 6 × the upper limit of normal 
(ULN), albumin > 2.8 mg/dL and serum creati-
nine < 1.5 × ULN. 
Exclusion criteria were previous radiation ther-
apy (RT) to the upper abdomen, clinically detect-
able ascites, encephalopathy, main or common 
bile duct involvement, esophageal bleeding in the 
previous 3 months, large esophageal varices with 
red color signs or patients with severe gastrointes-
tinal symptoms. Concomitant systemic treatment 
was not allowed; a minimum interval of 4 weeks 
from the last systemic treatment was required be-
fore enrollment. Patients with other malignant 
neoplasms were allowed if HCC carried a worse 
prognosis. 
Patients that fulfilled the inclusion criteria and 
agreed to participate in the study signed written 
informed consents. The study was conducted in 
accordance with the ethical guidelines of the Dec-
laration of Helsinki and posterior revisions [22], 
as reflected in a priori approval by the institutional 
review committee. 
radiation planning and treatment 
delivery
Patients were immobilized using a customized 
vacuum cushion (body fix®) and had abdominal 
compression or Active Breathing Control® to re-
duce liver motion throughout respiration. Multi-
phasic Computed Tomography (CT) for radiation 
planning was acquired in the exhale breath-hold. 
Additionally, fluoroscopy and four-dimensional CT 
(4D-CT) were performed to evaluate liver motion. 
Gross Tumor Volume (GTV) was defined as 1) 
arterial-enhancing lesions with washout on venous 
or delayed phase or 2) washout in venous or delayed 
phase for infiltrative HCC. To improve target de-
lineation accuracy, diagnostic magnetic resonance 
imaging (MRI) co-registration was performed as 
needed. There was no clinical target volume (CTV) 
expansion (CTV = GTV). Fluoroscopy and 4D-CT 
information were used to account for tumor mo-
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tion through the respiratory cycle to generate the 
internal target volume (ITV). A 5 mm margin was 
added to the ITV to generate the planning target 
volume (PTV). 
Doses of 30 to 50  Gy in 5 daily fractions were 
prescribed using an isotoxic approach as proposed 
by RTOG 1112 [23]. We prescribed the highest 
dose that could meet the mean liver dose, according 
to Table S1 (supplementary material online). Plan-
ning was performed using Volumetric Modulated 
Arc Therapy (VMAT). Treatment was delivered in 
consecutive working days with 6 MV linear ac-
celerator Elekta Axesse®. At each treatment frac-
tion, fluoroscopy and CBCT were performed, with 
6-degree couch correction and reimaging before 
treatment. No fiducials were used.
Systemic therapy after SBRT was not standard-
ized in the trial protocol. Patients typically received 
sorafenib after progression to the trial treatment.
endpoints 
Our primary endpoint was local progression-free 
survival (LPFS), measured per modified Response 
Evaluation Criteria in Solid Tumors (mRECIST) 
[24] and defined as the absence of increase of 20% 
in the sum of all diameters of treated lesions. Pre-
existing TVT progression was considered local 
progression. Imaging modality was preferentially 
CT. MRI was ordered as needed for additional le-
sion conspicuity. Baseline imaging modality (CT 
or MRI) was maintained throughout follow-up for 
consistency. 
Secondary endpoints were liver progres-
sion-free survival (PFS), defined as absence of new 
liver lesions or new TVT; distant PFS, defined 
as the absence of extra-hepatic disease; overall 
survival (OS) and toxicity measured by the Com-
mon Terminology Criteria for Adverse Events 
(CTCAE) v.4.0. All time-to-event endpoints were 
measured from the start of SBRT. Patients that 
received liver transplant were censored for LPFS 
at the day of transplantation, but remained at-risk 
for other endpoints. 
Patients were followed monthly in the first 3 
months and every 3 months thereafter. Liver imag-
ing was performed every 3 months. 
statistical analysis
This pilot study was planned with a convenience 
sample size of 25 patients. 
Survival was estimated by the method of Ka-
plan-Meier and compared using the log-rank 
test. Continuous variables were compared using 
Wilcoxon rank-sum test. HR were calculated us-
ing Cox regression. Statistical significance was 
set to p ≤ 0.05. There were no corrections for 
multiple comparisons. We used Stata Release 14, 
College Station, TX for statistical analyses. The 
study is registered at ClinicalTrials.gov number 
NCT02221778. 
This research did not receive any specific grant 
from funding agencies in the public, commercial, 
or not-for-profit sectors.
results
From November 2014 through August 2019, 
twenty-six patients received SBRT and were ana-
lyzed. Fig. S1 shows the flow diagram of patients 
(supplementary material online). Median follow-up 
for patients alive was 28.5 months (range 6.2–65.7 
months). No patient was lost to follow-up. 
Table 1 describes patients’ characteristics. Me-
dian age was 69 years, with eleven (42%) patients 
older than 70 years of age. Underlying liver disease 
was hepatitis C, hepatitis B and alcohol-related, 
in respectively, 50%, 23% and 19% of patients. All 
patients were Child-Pugh score A. Three (12%) 
patients received previous hepatectomy, one re-
ceived RFA and 21 (81%) patients received previ-
ous TACE. Of these, the status after the last TACE 
was progressive disease in 62% and stable disease 
(no response) in 38% of patients. TVT was present 
in 7 (27%) patients, and was the main reason of 
ineligibility for TACE. Median alpha-fetoprotein 
(AFP) was 171.7 ng/mL (range 4.2–5,494 ng/mL) 
and 13 (50%) patients had AFP > 200 ng/mL. Medi-
an SBRT prescription dose was 40 Gy (range 30–50 
Gy) in 5 fractions. 
Local progression-free survival
LPFS at 1 and 2 years were, respectively, 86% 
(95% CI: 61–95%) and 64% (95% CI: 29–85%). Me-
dian LPFS was 34.7 months (Fig. 1A). Patients that 
received SBRT dose ≥ 45 Gy had a higher chance 
of local control. Median LPFS for patients that re-
ceived ≥ 45 Gy was not reached vs. 12.1 months in 
patients that received < 45 Gy (p = 0.037; HR = 0.12, 
95% CI: 0.01–1.19) (Fig. 1B). Table 2 shows univariate 
analysis of prognostic factors associated with LPFS, 
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liver PFS and OS. Previous TACE had no impact on 
LPFS (p = 0.811; HR = 0.76, 95% CI: 0.08–6.92).
Liver PFS at 1 and 2 years were, respectively, 52% 
(95% CI: 28–71%) and 26% (95% CI: 8–48%) Me-
dian Liver PFS was 12.1 months (Fig. 2). Hepatitis 
C negatively impacted liver PFS, with HR 3.58 (95% 
CI: 1.15–11.18; p = 0.02) (Tab. 2). 
Distant PFS at 1 and 2 years were similar at 77% 
(95% CI: 53–90%). Median distant PFS was not 
reached. 
Median survival was 21 months. OS at 1 and 2 
years were, respectively, 79% (95% CI: 57–91%) 
and 42% (95% CI: 22–61%) (Fig. 3). Higher SBRT 
dose, presence of TVT, AFP > 200 ng/mL were not 
statistically associated with OS, whereas patients 
with Hepatitis C had worse survival (p = 0.046; 
HR = 2.56; 95% CI: 0.98–6.67) (Tab. 2). We recom-
mend caution in interpreting these results due to 
our small sample size. 
table 1. patients characteristics
Characteristics n (%) Median (range) 













hepatitis B 6 (23%)
hepatitis c 13 (50%)
alcohol 5 (19%)
Nash 2(8%)
schistosomiasis mansoni 1 (4%)







Number of lesions 47 (100%) 1 (1–4)
size of largest lesion [cm] 3.8 (1.5–10)
tumor vascular thrombosis 7 (27%)
Dose [Gy] 40 (30–50)
AFP 
> 200 ng/mL 13 (50%)
≤ 200 ng/mL 13 (50%)
baseline laboratory values
aFp [ng/mL] 171.7 (4.2–5494)
aLT [U/L] 39 (7–119)
asT [U/L] 44 (10–162)
aLp [U/L] 103 (59–246)
GGT [U/L] 109 (19–612)
Bilirubin [mg/dL] 0.9 (0.2–1.9)
albumin [g/dL] 4.0 (3.3–4.8)
INr 1.14 (1.00–1.49)
creatinin [mg/dL] 0.87 (0.56–1.32)
platelets [× 109/L] 117 (52–300)
ecOG — eastern cooperative Oncology Group; BcLc — Barcelona clinic 
Liver cancer classification; Nash — nonalcoholic steatohepatitis;  
Tace — transarterial chemoembolization; Gy — Gray; aFp — alpha-feto- 
protein; aLT — alanine aminotransferase; asT — aspartate amino-
transferase; aLp — alkaline phosphatase; GGT — gamma-glutamyl 
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Figure 1. Local progression-free survival. Kaplan-Meier 
estimates of local progression-free survival (A) all patients.  
Dashed lines depict 1- and 2-year local progression-free 
survival of 86% and 64% (b) By prescription dose of 45 Gy. 
patients receiving dose ≥ 45 Gy had better local control  
(p = 0.037; log-rank test)
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table 2. Univariate analysis of prognostic factors for survival endpoints
Prognostic factor Median (months) HR (95% CI) p
Local progression-free survival
Total dose [Gy]
≥ 45 Not reached 0.12 (0.01–1.19) 0.037
< 45 12.1
hepatitis c
Yes Not reached 0.26 (0.03–2.25) 0.189
No 16.8
Tumor vascular thombosis
Yes Not reached 2.1 (0.39–14.4) 0.326
No 34.7
alpha-fetoprotein [ng/mL]
> 200 34.7 2.74 ( 0.49–15.20) 0.230
≤ 200 Not reached
Number of lesions
3 or more Not reached 0.71 (0.08–6.27) 0.758
1 or 2 34.7
Diameter of largest lesion
> 3cm 16.8 1.06 (0.18–5.91) 0.946
≤ 3cm 34.7
previous Tace




≥ 45 15.9 0.64 (0.21–1.92) 0.428
< 45 9.8
hepatitis c
Yes 8.9 3.58 (1.15–11.18) 0.019
No 15.9
Tumor vascular thombosis
Yes 8.9 1.49 (0.46–4.81) 0.492
No 15.4
alpha-fetoprotein [ng/mL]
> 200 9.1 1.62 (0.55–4.73) 0.364
≤ 200 15.4
Number of lesions
3 or more 7.1 1.11 (0.34–3.58) 0.850
1 or 2 15.4
Diameter of largest lesion
> 3cm 12.1 0.69 (0.20–2.33) 0.550
≤ 3cm 9.1
previous Tace
Yes 12.1 1.19 (0.26–5.34) 0.817
No 9.8
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Toxicity
Treatment was well tolerated, without treat-
ment-related grade 3 or 4 clinical toxicities. Grade 
3 or 4 laboratory toxicities occurred in 7 (27%) 
patients (Tab. 3). Most of these were transient, oc-
curring 1 to 3 months following treatment and sub-
siding thereafter. One patient died of progressive 
liver failure 6 months following treatment. After 
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Figure 2. Liver progression-free survival. Kaplan-Meier 
estimate of liver progression-free survival. Dashed lines 
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Figure 3. Overall survival. Kaplan-Meier estimate of overall 
survival. Dashed lines depict 1- and 2-year overall survival 
of, respectively, 79% and 42%
table 2. Univariate analysis of prognostic factors for survival endpoints
Prognostic factor Median (months) HR (95% CI) p
Overall survival
Total dose [Gy]
≥ 45 26.5 0.82 (0.32–2.11) 0.686
< 45 18.2 
hepatitis c
Yes 14.3 2.56 (0.98–6.67) 0.046
No 26.5
Tumor vascular thombosis
Yes 17.6 1.51 (0.56–4.08) 0.408
No 22.0
alpha-fetoprotein [ng/mL]
> 200 17.6 1.80 (0.70–4.64) 0.212
≤ 200 22.0
Number of lesions
3 or more 36.7 0.61 (0.20–1.88) 0.739
1 or 2 21.0
Diameter of largest lesion
> 3 cm 18.2 0.85 (0.32–2.21) 0.394
≤ 3 cm 24.9
previous Tace
Yes 24.9 0.36 (0.11–1.22) 0.088
No 17.6
Tace — transarterial chemoembolization
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the death not directly related to SBRT, but possibly 
related. A detailed discussion of the case can be 
found online in the supplementary appendix.
radiologic response
Eighty-nine percent of patients had objective re-
sponse per mRECIST, with complete and partial 
response in, respectively, 54% and 35% of patients 
(Table S2, online). In patients who responded, me-
dian time for the best response was 3.7 months 
(IQR: 3.1–6.8 months; range 2–12.6 months). Fig-
ure 4 shows the case of an 80-year-old woman with 
hepatitis B and a single 4 cm HCC lesion that was 
treated to 45 Gy. The lesion responded continuously 
until reaching complete response per mRECIST 
at 12.6 months. Following complete response, the 
non-enhancing lesion continued to reduce until 31 
months. 
alpha-fetoprotein
Median pretreatment AFP was 171 ng/mL (IQR: 
12–868 ng/mL); 3 months after SBRT, median 
AFP reduced to 12 ng/mL (IQR: 6.3–85.6 ng/mL) 
(p = 0.003; Wilcoxon signed-rank test for paired 
samples) (Fig. S2, Supplementary File). Before 
treatment, 21 (81%) patients had AFP above ULN 
(> 10 ng/mL). For these, AFP was a good marker 
of response.
Discussion
To the best of our knowledge, no prospective 
data has been reported using SBRT to treat HCC in 
Latin America. Our findings indicate the technique 
is feasible in a Brazilian referral cancer center. 
Our study suggests that SBRT has substantial 
activity against HCC in our patient population. We 
achieved 1-year LPFS of 86% in a sample of pre-
viously treated patients, with median lesion size 
of 3.8 cm, AFP > 200 ng/mL in 50% and TVT 
in 27% of patients. Objective response was seen 
in 88% of patients, with 54% achieving complete 
response during follow-up. Patients that received 
SBRT dose ≥ 45 Gy had a significant longer LPFS. 
Other prospective SBRT trials treating HCC-on-
ly have reported similar results, with Bujold et al. 
reporting local control at 1 year of 87% [11] and 
Andolino et al. with local control at 2 years of 90% 
table 3. Treatment related toxicity
Toxicity Grade 1 Grade 2 Grade 3 Grade 4
clinical 10 (38%) 5 (19%) 0 (0%) 0 (0%)
Nausea 5 (19%) 2 (8%) 0 (0%) 0 (0%)
anorexia 7 (27%) 0 (0%) 0 (0%) 0 (0%)
Diarrhea 3 (12%) 0 (0%) 0 (0%) 0 (0%)
Fatigue 2 (8%) 1 (4%) 0 (0%) 0 (0%)
Gastritis 3 (12%) 1 (4%) 0 (0%) 0 (0%)
Dyspepsia 3 (12%) 1 (4%) 0 (0%) 0 (0%)
chest wall pain 2 (8%) 1 (4%) 0 (0%) 0 (0%)
rib fracture 0 (0%) 1 (4%) 0 (0%) 0 (0%)
pneumonitis 0 (0%) 1 (4%) 0 (0%) 0 (0%)
radiation dermatitis 1 (4%) 0 (0%) 0 (0%) 0 (0%)
Laboratory 7 (27%) 12 (46%) 6 (23%) 1 (4%)
platelet 12 (46%) 8 (31)%) 4 (15%) 0 (0%)
Bilirubin 9 (35%) 9 (35%) 1 (4%) 1 (4%)
aLT 17 (65%) 3 (12%) 0 (0%) 0 (0%)
asT 14 (54%) 5 (19%) 2 (8%) 0 (0%)
aLp 15 (58%) 2 (8%) 0 (0%) 0 (0%)
INr 13 (50%) 1 (4%) 0 (0%) 0 (0%)
albumin 6 (23%) 3 (12%) 0 (0%) 0 (0%)
Toxicity graded according to the common Terminology criteria for adverse events v4.0. Data presented as n (%). aLT — alanine aminotransferase;  
asT — aspartate aminotransferase; aLp — alkaline phosphatase; INr — international normalized ratio
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[10]. A recent meta-analysis from thirty-two pro-
spective and retrospective studies involving 1950 
HCC patients reported pooled 1- and 2-year lo-
cal control rates of 85.7% (95% CI: 80.1–90.0) and 
83.6% (77.4–88.3) [25]. Taken together, these re-
sults suggest SBRT is an adequate strategy for HCC 
not candidate to other therapies. This strategy could 
be further explored in elderly and frail patients that 
carry a greater risk to invasive procedures [26].
It is of note that LPFS was similar between pa-
tients that received TACE and patients that did 
not receive it due to ineligibility. Although upfront 
SBRT is feasible in localized HCC prior to TACE, 
the clinical benefit of such approach is currently 
under investigation [27]. 
In our study, radiologic and laboratory response 
were not immediate, requiring at least 3 months 
for initial evaluation. Our median time for the best 
radiological response was 3.7 months, with patients 
achieving complete response up to one year after 
treatment. After RT, cancer cells undergo reproduc-
tive death, that is, loss of capacity to reproduce in-
Figure 4. complete response after stereotactic body radiotherapy (sBrT). Images of an 80-year-old patient who underwent 
sBrT with 45 Gy to a single 4 cm lesion (white arrow). A. pre-treatment magnetic resonance imaging (MrI); b. sBrT isodose 
curves. c–F. Follow-up MrIs showing continuous reduction of the treated lesion. In images (c) and (D), transient alterations 
due to lower isodoses are seen in surrounding liver parenchyma. In images (E) and (F), the gallbladder, with its characteristic 
homogeneous contrast enhancement, is seen to the right of the arrow. Images are not at the same level due to changes  




Reports of Practical Oncology and Radiotherapy 2021, vol. 26, no. 2
https://journals.viamedica.pl/rpor234
definitely [28]. A cell may still be physically intact, 
may be able to make proteins or synthesize DNA, 
but it has lost its reproductive integrity. Most cells 
will die while attempting to divide (mitotic death), 
while some will die by apoptosis [28]. Therefore, 
after SBRT, from a radiobiological standpoint, the 
presence of early arterial enhancement with early 
“washout” should not be considered a sign of vi-
ability. Until there is no volume progression, le-
sions should be considered controlled [10, 11, 29, 
30]. Such an approach differs from TACE or ra-
diofrequency ablation and highlights the need to 
understand RT mechanisms of action to interpret 
follow-up images. 
The possibility of treating TVT with SBRT ex-
pands treatment strategies to this group of patients 
that is usually not candidate to local therapy. In 
our study, median survival for patients with TVT 
was 17.6 months. Yoon et al. conducted a random-
ized study comparing TACE plus conformal RT vs 
sorafenib in patients with TVT and absence of dis-
tant metastases [31]. Among 90 patients enrolled, 
79% had multiple lesions, with median size of the 
largest lesion of 9.7 cm. TACE + RT had longer 
time to progression (4.2 months vs. 2.8 months; 
p < 0.001) and median survival (13.1 months vs. 
10.2 months; p = 0.04). In our opinion, current 
evidence suggests that RT is an adequate local treat-
ment even in the context of TVT.
Despite our good local control, failure in the 
remaining liver continues to be a problem. As re-
ported by Takeda et al. [14], this was our main pat-
tern of failure. In our exploratory analysis, baseline 
hepatitis C was associated with progression in the 
untreated liver.  
Our median survival of 21 months is within the 
range of previously prospective studies using SBRT 
[9–14]. Survival is highly influenced by patient’s 
baseline characteristics. For instance, Bujold et al., 
in a sample with a median tumor size of 7.2 cm, 
55% TVT and 12% extra-hepatic disease, reported 
median survival of 17 months [11]. Andolino et al. 
studied SBRT in a more favorable population, with 
single lesion in 85% of patients, no TVT, median 
lesion size of 3 cm and 10% prior therapy. The au-
thors reported a median survival of 44 months [10].
In comparison with systemic therapy, the SHARP 
study [32] reported median survival of 10.7 months 
in a sample with 36% of TVT and 53% of extra-he-
patic disease. The Asia Pacific study [33] reported 
median survival of 6.5 months in a sample with 
36% of TVT and 69% of extra-hepatic disease. Rec-
ognizing the tremendous limitations of compari-
sons across studies, survival of SBRT trials compare 
favorably to sorafenib. 
Toxicity was acceptable in our study, with no 
grade 3 or 4 clinical toxicities. One death was possi-
bly related to treatment and is within the previously 
reported range of up to 6.9% [11].
Our study has several limitations. First, it’s a pro-
spective pilot study with a small sample size. Our 
accrual period was long and reflect the nature of 
salvage treatment in a complex disease. After failure 
or ineligibility for TACE, a significant proportion 
of patients had a worsening liver function or had 
tumors beyond the inclusion criteria of our trial. 
Our study generates hypothesis and highlights the 
importance of conducting worldwide representa-
tive phase III trials to definitely establish the role of 
SBRT in the treatment of HCC. 
There are two ongoing phase III randomized tri-
als of SBRT in HCC. IAEA E33036 [27] is compar-
ing TACE vs SBRT in the setting of unresectable 
HCC unsuitable for conventional ablative therapies. 
RTOG 1112 [23] is currently testing the suggested 
benefit of adding SBRT to sorafenib for locally ad-
vanced HCC. 
conclusion
In conclusion, SBRT is feasible in our Brazilian 
population. Our study suggests that higher SBRT 
dose improves local progression-free survival with 
acceptable toxicity. It should be considered as 
a treatment option in HCC patients unresponsive 
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